Gracell Biotechnologies Inc. stock is up 23.35% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate. GC019F is in Phase I clinical trial for the. treatment of adult B cell acute lymphoblastic leukemia (B-ALL)